聚乙二醇化G-CSF给药后时间与FDG PET/CT骨髓摄取的关系:确定最小间隔
该回顾性研究纳入70例接受化疗的肿瘤患者,比较培非格司亭给药后35天内(研究扫描)与未给药时(参考扫描)的FDG PET/CT骨髓和脾脏摄取。结果显示骨髓摄取随给药后时间延长而显著下降,视觉评分3或4分在给药后约3周内持续存在,22天后无此类病例,推荐PET/CT在培非格司亭给药后至少间隔3周进行。
要点
- 培非格司亭给药后22天内骨髓摄取视觉评分可达3-4分,可能干扰PET/CT判读。
- 推荐FDG PET/CT在培非格司亭给药后至少间隔3周进行。
- 脾脏摄取变化与给药间隔无关,上臂骨髓摄取亦无显著关联。
关键影像表现/征象
- 骨髓摄取视觉评分4分见于给药后7-21天,3分见于12-22天,2分见于12-28天,1分见于14-35天。
- 评分3或4分的患者比例:7-13天为94.4%,14-21天为58.1%,22-28天为6.7%,29-35天为0%。
- 7-21天期间71.4%患者评分3或4分,22-35天期间仅4.8%评分3且0%评分4分。
- 颈椎、胸椎、腰椎、骨盆及下肢骨髓SUVmean百分比变化随间隔延长显著增加(p<.05),上肢和脾脏无显著关联(p>.05)。
诊断标准与关键数值
- 视觉评分标准:1分无异常摄取;2分临床不显著摄取;3分临床显著可能干扰判读;4分临床显著预期干扰判读。
- 骨髓SUVmean百分比变化:间隔7-13天 vs 29-35天,颈椎32.3%±18.2% vs 11.5%±17.3%,胸椎42.2%±18.3% vs 21.3%±14.2%,腰椎47.2%±19.8% vs 19.1%±13.9%,骨盆51.1%±25.8% vs 12.7%±11.3%,下肢53.0%±25.6% vs 4.4%±14.1%。
临床应用与阅片要点
- 阅片时注意询问培非格司亭给药时间,给药后3周内骨髓弥漫性摄取增高可能干扰判读。
- 给药后22天内的PET/CT若见骨髓摄取评分3或4分,应结合临床考虑是否为药物影响。
- 脾脏摄取不受给药间隔影响,上臂骨髓摄取亦无显著变化,可辅助鉴别。
局限性
- 回顾性单中心研究,样本量70例,可能存在选择偏倚。
- 参考扫描时间窗不一致(给药前至少4个月或末次给药后至少3个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Pegfilgrastim administration after chemotherapy increases bone marrow and spleen FDG uptake. Consensus is lacking regarding the optimal interval between pegfilgrastim administration and FDG PET/CT. OBJECTIVE. The purpose of this study was to assess the association between bone marrow and spleen uptake and the interval between pegfilgrastim administration and FDG PET/CT. METHODS. This retrospective study included 70 oncology patients (mean age, 64 ± 12 [SD] years; 48 men, 22 women) receiving chemotherapy who underwent FDG PET/CT (study scan) within 35 days after pegfilgrastim administration and who underwent additional FDG PET/CT at least 4 months before pegfilgrastim initiation or at least 3 months after last pegfilgrastim administration (reference scan). A nuclear medicine physician recorded the SUVmean for normal osseous structures and spleen and assessed bone marrow uptake using a 4-point visual scale (1, no abnormal uptake; 2, clinically insignificant uptake; 3, clinically significant uptake possibly interfering with interpretation; 4, clinically significant uptake expected to interfere with interpretation). RESULTS. Percentage change in SUVmean between reference and study scans significantly increased (p < .05) as the interval increased for five sites (i.e., for patients with interval of 7-13 vs 29-35 days, mean percentage change was 32.3% ± 18.2% vs 11.5% ± 17.3% for cervical vertebra, 42.2% ± 18.3% vs 21.3% ± 14.2% for thoracic vertebra, 47.2% ± 19.8% vs 19.1% ± 13.9% for lumbar vertebra, 51.1% ± 25.8% vs 12.7% ± 11.3% for pelvis, and 53.0% ± 25.6% vs 4.4% ± 14.1% for lower extremity); percentage change was not associated with the interval for upper extremity or spleen (p > .05). Visual uptake scores of 4, 3, 2, and 1 were observed in days 7-21, 12-22, 12-28, and 14-35, respectively. Percentage of patients with a score of 3 or 4 was 94.4% for days 7-13, 58.1% for days 14-21, 6.7% for days 22-28, and 0% for days 29-35. A total of 71.4% of patients had a score of 3 or 4 on day 7-21, whereas 4.8% had a score of 3 and 0% had a score of 4 on days 22-35. CONCLUSION. A visual uptake score of 3 or 4 was consistently observed throughout an approximately 3-week interval following pegfilgrastim administration, without any such case beyond 22 days. CLINICAL IMPACT. We recommend a preferred interval of at least 3 weeks after pegfilgrastim administration before PET/CT.
引用
- Minamimoto R, Baratto L, Iagaru A, et al. Association Between Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval. AJR Am J Roentgenol. 2021. PMID: 34467784. doi:10.2214/AJR.21.26480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。